Atrial flow regulator for drug-resistant pulmonary hypertension in a young child
Corresponding Author
Ellen Vanhie MD
Department of Pediatrics, Pediatric Cardiology, Amsterdam University Hospital, Amsterdam, The Netherlands
Correspondence
Ellen Vanhie, Department of Pediatrics, Pediatric Cardiology, Amsterdam University Hospital, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Email: [email protected]
Search for more papers by this authorKristof VandeKerckhove MD, PhD
Department of Pediatrics, Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorNikolaus A. Haas MD, PhD
Department of Pediatrics, Pediatric Cardiology, LMU Klinikum, München, Germany
Search for more papers by this authorDaniel De Wolf MD, PhD
Department of Pediatrics, Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium
Department of Pediatrics, Pediatric Cardiology, Brussel University Hospital, Brussels, Belgium
Search for more papers by this authorCorresponding Author
Ellen Vanhie MD
Department of Pediatrics, Pediatric Cardiology, Amsterdam University Hospital, Amsterdam, The Netherlands
Correspondence
Ellen Vanhie, Department of Pediatrics, Pediatric Cardiology, Amsterdam University Hospital, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Email: [email protected]
Search for more papers by this authorKristof VandeKerckhove MD, PhD
Department of Pediatrics, Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorNikolaus A. Haas MD, PhD
Department of Pediatrics, Pediatric Cardiology, LMU Klinikum, München, Germany
Search for more papers by this authorDaniel De Wolf MD, PhD
Department of Pediatrics, Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium
Department of Pediatrics, Pediatric Cardiology, Brussel University Hospital, Brussels, Belgium
Search for more papers by this authorAbstract
This case describes the successful implantation of an Occlutech Atrial Flow Regulator in a young child with idiopathic pulmonary hypertension and recurrent syncope despite targeted combination therapy, with subsequent relief of symptoms.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing not applicable - no new data generated.
REFERENCES
- 1Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1): 67-119.
- 2Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl): D117-D126.
- 3Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015; 132(21): 2037-2099.
- 4Lammers AE, Derrick G, Haworth SG, Bonhoeffer P, Yates R. Efficacy and long-term patency of fenestrated amplatzer devices in children. Catheter Cardiovasc Interv. 2007; 70(4): 578-584.
- 5Mainzer G, Goreczny S, Morgan GJ, et al. Stenting of the inter-atrial septum in infants and small children: indications, techniques and outcomes. Catheter Cardiovasc Interv. 2018; 91(7): 1294-1300.
- 6Lehner A, Schulze-Neick I, Fischer M, et al. The creation of an Interatrial right-to-left shunt in patients with severe, irreversible pulmonary hypertension: rationale, devices, outcomes. Curr Cardiol Rep. 2019; 21(5): 31.
- 7Rajeshkumar R, Pavithran S, Sivakumar K, Vettukattil JJ. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension. Catheter Cardiovasc Interv. 2017; 90(7): 1145-1153.
- 8Takatsuki S, Yanai S, Ikehara S, Nakayama T, Matsuura H. Clinical effects of syncope on disease severity and adverse outcomes in children with idiopathic and heritable pulmonary arterial hypertension. Pediatr Cardiol. 2019; 40(1): 209-214.
- 9Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012; 379(9815): 537-546.
- 10Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019; 38(9): 879-901.
- 11Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015; 373(26): 2522-2533.
- 12Bauer A, Khalil M, Schmidt D, et al. Creation of a restrictive atrial communication in pulmonary arterial hypertension (PAH): effective palliation of syncope and end-stage heart failure. Pulm Circ. 2018; 8(2): 1-9.
- 13Khan MS, Memon MM, Amin E, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2019; 156(1): 53-63.
- 14Haas NA, Soetemann DB, Ates I, et al. Closure of secundum atrial septal defects by using the occlutech occluder devices in more than 1300 patients: the IRFACODE project: a retrospective case series. Catheter Cardiovasc Interv. 2016; 88(4): 571-581.
- 15Lehner A, Schulze-Neick I, Haas NA. Creation of a defined and stable Fontan fenestration with the new Occlutech atrial flow regulator (AFR®). Cardiol Young. 2018; 28(8): 1062-1066.
